Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-90
SponsorZhejiang University
About this trial
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
clinically diagnosed as IPMN;
without other malignant tumor;
agree to sign informed consent.
Disqualifiers
with mental disorders which can affect cognition and cooperation;
with serious blood diseases or taking drugs that can affect peripheral blood
Trial population
Patients ought to meet all inclusion and exclusion criteria. In addition, the patient of the prospective cohort should be thoroughly informed about the study, including the study visit schedule and required evaluations and all regulatory requirements for informed consent. The written informed consent of the prospective cohort should be obtained from the patient prior to enrollment.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Observation
Other interventionThis is an observational study.
Treatment groups
5,000 Participants
are divided into 1 treatment groupGroup A: Prospective IPMN cohort1 intervention
Trial outcomes
Primary outcomes
1
The accuracy of IPMN malignant transformation
Time frame
Up to 10 yearsSecondary outcomes
1
the probability of IPMN malignant transformation
Time frame
Up to 10 years2
rates of surgical resection
Time frame
Up to 10 years3
survival after surgery
Time frame
Up to 10-15 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Zhejiang University
Lead sponsor
The Second Hospital of Hebei Medical University
Collaborator
Second Affiliated Hospital of Nanchang University
Collaborator
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Collaborator
Huizhou Municipal Central Hospital
Collaborator
Source ClinicalTrials.gov